GNRHR
ENSG00000109163
Target class
GPCR
Chromosome
4
Approved drugs
18
Clinical candidates (approved and in development)
25
- Approved drugs
- 18
- Clinical candidates (approved and in development)
- 25
- Chemical probe available
- Yes
- Other names
- LHRHR
- Target name
- GNRHR
- Gene name
- Gonadotropin releasing hormone receptor
- Gene symbol
- GNRHR
- Previous gene symbols
- GRHR
- Protein name
- Gonadotropin-releasing hormone receptor (GnRH receptor) (GnRH-R)
- Gene biotype
- Protein coding
- Gene family
- Gonadotropin releasing hormone receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 6.38
- Tissue specificity (Gini)
- 0.591
- Tissue specificity (tau)
- 0.973
- KEGG gene identifiers
- hsa:2798
- Protein interaction confidence
- 0.8665
- Protein interaction partners
- 16
- R-HSA-375281
- R-HSA-416476
- End position
- 67754388
- Start position
- 67737118
- Chromosome
- 4
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.973325
- Expression inequality (Gini)
- 0.590981
Expression in transcripts per million
- Pituitary
- 6.38
- Vagina
- 0.5
- Brain - Cerebellum
- 0.42
- Cells - EBV-transformed lymphocytes
- 0.42
- Brain - Cerebellar Hemisphere
- 0.41
Expression in transcripts per million
- Pituitary6.38
- Vagina0.5
- Brain - Cerebellum0.42
- Cells - EBV-transformed lymphocytes0.42
- Brain - Cerebellar Hemisphere0.41
- Thyroid0.37
- Nerve - Tibial0.33
- Esophagus - Mucosa0.32
- Cervix - Endocervix0.28
- Cervix - Ectocervix0.26
- Minor Salivary Gland0.25
- Brain - Frontal Cortex (BA9)0.24
- Ovary0.23
- Prostate0.23
- Kidney - Medulla0.21
- Brain - Cortex0.21
- Cells - Cultured fibroblasts0.21
- Uterus0.19
- Bladder0.19
- Brain - Hypothalamus0.17
- Testis0.16
- Brain - Anterior cingulate cortex (BA24)0.16
- Artery - Coronary0.16
- Brain - Nucleus accumbens (basal ganglia)0.16
- Artery - Aorta0.15
And 29 more, listed on the interactive page.
Biological processes
- GO:0007186
- GO:0005886
- GO:0016020
Molecular functions
- GO:0004968
Related records
Trials (1,215)
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- 12-week Open-label Evaluation of Efficacy and Safety of Indacaterol
- 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
- 90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment
- 90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
- 90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment
- 90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients
- A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
- A Clinical Study of KLH-2109 in Patients With Endometriosis
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
- A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
- A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
- A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
- A Degarelix Trial in Patients With Prostate Cancer
- A Food Effect Study of TAK-385 Final Formulation
Drugs (33)
- Abarelix Gonadotropin-releasing hormone receptor antagonist
- Acyline Gonadotropin-releasing hormone receptor antagonist
- Buserelin Gonadotropin-releasing hormone receptor agonist
- Cetrorelix Gonadotropin-releasing hormone receptor antagonist
- Cetrorelix acetate Gonadotropin-releasing hormone receptor antagonist
- Degarelix Gonadotropin-releasing hormone receptor antagonist
- Degarelix acetate Gonadotropin-releasing hormone receptor antagonist
- Elagolix Gonadotropin-releasing hormone receptor antagonist
- Elagolix sodium Gonadotropin-releasing hormone receptor antagonist
- Ganirelix Gonadotropin-releasing hormone receptor antagonist
- Ganirelix acetate Gonadotropin-releasing hormone receptor antagonist
- Gonadorelin Gonadotropin-releasing hormone receptor agonist
- Gonadorelin acetate Gonadotropin-releasing hormone receptor agonist
- Gonadorelin hydrochloride Gonadotropin-releasing hormone receptor agonist
- Goserelin Gonadotropin-releasing hormone receptor agonist
- Goserelin acetate Gonadotropin-releasing hormone receptor agonist
- Histrelin Gonadotropin-releasing hormone receptor agonist
- Histrelin acetate Gonadotropin-releasing hormone receptor agonist
- Leuprolide Gonadotropin-releasing hormone receptor agonist
- Leuprolide acetate Gonadotropin-releasing hormone receptor agonist